November 2016

Dear Colleague,

Welcome to the fourth edition of our HER2-Positive Breast Cancer Updates newsletter. If you haven't yet watched the full roundtable discussion that my colleagues and I filmed recently, I invite you to take a look at Chapter 1. You'll be able to listen to the panel members share our differing perspectives on the importance of a multidisciplinary team in treating this challenging malignancy.

I've also provided articles on such topics as how breast cancers use white blood cells to avoid immune defenses; the role of CITED2 in breast carcinoma as a prognostic predictor associated with proliferation, migration, and chemoresistance; and how trastuzumab as preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.

Please share this newsletter with your colleagues and don't hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at

Until next time, take a look at the links I've gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

Heather Greene, MSN, FNP, AOCN®
The West Cancer Center
Memphis, Tennessee 


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.